Bristol Myers Squibb signs $15.2 billion drug deal with China's Hengrui as patent cliff looms

Details werden geladen...

https://thenextweb.com/news/bms-hengrui-china-pharma-patent-cliff

Teilen bei Facebook
Teilen bei Twitter
Teilen bei Pinterest
Per Mail empfehlen

Bristol Myers Squibb signs $15.2 billion drug deal with China's Hengrui as patent cliff looms

BMS is paying Hengrui $15.2 billion for 13 early-stage drugs across oncology and immunology. The deal exposes how Big Pharma's patent cliff has made Chinese innovation indispensable.

Bristol Myers Squibb partners with China's Hengrui Pharma on a dozen drugs

https://www.statnews.com/2026/05/12/bristol-myers-squibb-hengrui-china-licensing-deal/

Login

Bristol Myers Squibb signs $15.2 billion drug deal with China's Hengrui as patent cliff looms

Ähnliche Seiten

Bristol Myers Squibb partners with China's Hengrui Pharma on a dozen drugs